Table 1.
Characteristics of cancer patients undergoing surgery at Oxford HPB Surgery Unit from 1/3/2020 to 30/4/2020
| HPB patients population | |
|---|---|
| Patient age (years), median (range) | 64 (38-78) |
| Patient gender, F/M, n (%) | 16 (53·3)/14 (46·7) |
| Main indication, n (%) | |
| CRLM | 12 (40) |
| NET | 6 (20) |
| Pancreatic adenocarcinoma | 3 (10) |
| Duodenal/ampullary tumour | 3 (10) |
| Bile ducts tumour | 3 (10) |
| Others |
2 (6·7) |
| Procedure, n (%) | |
| Pancreato-duodenectomy | 6 (20) |
| Distal pancreatectomy | 3 (10) |
| Major liver resection (≥3 segments) | 2 (6·7) |
| Liver segmentectomy (1-2 segments) | 11 (36·7) |
| Atypical liver resections | 4 (13·3) |
| Duodenal resection | 2 (6·7) |
| Cholecystectomy | 2 (6·7) |
| Postoperative ITU admission, n (%) | 2 (6·7) |
| Postoperative length of stay (days), median (range) * | 5 (2-44) |
| Postoperative SARS-CoV-2 RNA test | 7 (23·3) |
| Positive SARS-CoV-2 RNA test | 0 |
| Complications | 5 (16·7) |
| Clavien-Dindo grade I-II | 1 (3·3) |
| Clavien-Dindo grade III | 3 (10) |
| Clavien-Dindo grade IV | 0 |
| Clavien-Dindo grade V | 1 (3·3) |
| Total,n | 30 |
HPB, hepato-bilio-pancreatic, CRLM, colorectal liver metastases, NET, neuroendocrine tumours, ITU, intensive therapy unit,
*
n = 29.